Alzheimer disease is diagnosed postmortem by the density and spatial distribution of β-amyloid plaques and tau-bearing neurofibrillary tangles. The major protein component of each lesion adopts cross-β-sheet conformation capable of binding small molecules with submicromolar affinity. In many cases, however, Alzheimer pathology overlaps with Lewy body disease, characterized by the accumulation of a third cross-β-sheet forming protein, α-synuclein. To determine the feasibility of distinguishing tau aggregates from β-amyloid and α-synuclein aggregates with small molecule probes, a library containing 72,455 small molecules was screened for antagonists of tau-aggregatemediated changes in Thioflavin S fluorescence, followed by secondary screens to distinguish the relative affinity for each substrate protein.
Introduction
Alzheimer disease (AD) is the most common cause of dementia in the elderly population (Hebert et al., 2003) . It is defined and definitively diagnosed by the appearance of extracellular β-amyloid (Aβ) plaques and intracellular neurofibrillary lesions in the brain (Hyman, 1997) . Because AD progresses hierarchically, the density and spatial distribution of lesions also yield information on disease stage. However, all lesions are not equivalent in this regard, as total plaque density correlates poorly with cognitive decline and neurodegeneration (Braak and Braak, 1991; Terry et al., 1991) . For example, substantial numbers of diffuse plaques have been found in cognitively normal elderly individuals (Masliah et al., 1993) . In contrast, neurofibrillary lesion formation correlates more closely with disease progression (Braak and Braak, 1991) . These lesions consist of neurofibrillary tangles in neuronal cell bodies, neuropil threads within neuronal processes, and dystrophic neurites associated with neuritic plaques, each of which contains filamentous aggregates composed of the microtubule-associated protein tau (Buee et al., 2000) . Longitudinal studies have shown that tau lesions develop according to a common spatiotemporal pattern reflecting the sequence, type and severity of cognitive decline and neuronal loss (Ghoshal et al., 2002; Royall et al., 2002) . Most importantly, tau pathology appears in certain areas (such as deep temporal lobe) decades before neocortical Aβ deposition and signs of dementia can be detected (Duyckaerts and Hauw, 1997; Morsch et al., 1999) , and so can serve a prognostic function. Together these data suggest that the spatial distribution and density of neuritic lesions alone can contribute to the differential diagnosis and staging of AD.
Both tau and Aβ filaments consist of parallel, in register β-sheets aligned perpendicular to the fibril axis, resulting in a cross-β-sheet structure (Petkova et al., 2006) . The parallel orientation of β-sheets generates channels extending along the length of the filament (Krebs et al., 2005) to which aromatic molecules can bind via π−π interactions (Gazit, 2002) . Small molecules with these binding properties, including the benzothiazole aniline Pittsburgh Compound B (Klunk et al., 2004; Klunk et al., 2005) , bis-styryl benzene derivatives (Kung et al., 2003) , and substituted naphthalenes (Agdeppa et al., 2003) , have been developed as contrast agents for use in various modalities of whole brain imaging to capture the spatial distribution of amyloid lesions in situ (Klunk et al., 2004) . Most of these ligands bind cross-β-sheet structure common to both tau and β-amyloidbearing lesions (Berriman et al., 2003; Petkova et al., 2006) ,
